Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults

CJ. Strasburger, P. Vanuga, J. Payer, M. Pfeifer, V. Popovic, L. Bajnok, M. Góth, V. Olšovská, L. Trejbalová, J. Vadasz, E. Fima, R. Koren, L. Amitzi, M. Bidlingmaier, O. Hershkovitz, G. Hart, BM. Biller,

. 2017 ; 176 (3) : 283-294. [pub] 20161208

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013350

OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study's objective is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MOD-4023 administered once-weekly in GHD adults. DESIGN: 54 adults with GHD currently treated with daily GH were normalized and randomized into 4 weekly dosing cohorts of MOD-4023 at 18.5%, 37%, 55.5% or 123.4% of individual cumulative weekly molar hGH dose. The study included 2 stages: Stage A assessed the effectiveness and PK/PD profiles of the 4 dosing regimens of MOD-4023. Stage B was an extension period of once-weekly MOD-4023 administration (61.7% molar hGH content) to collect further safety data and confirm the results from Stage A. RESULTS: Dose-dependent response was observed for both PK and PD data of weekly MOD-4023 treatment. Insulin-like growth factor I (IGF-I) SDS levels were maintained within normal range. The 18.5% cohort was discontinued due to low efficacy. MOD-4023 was well tolerated and exhibited favorable safety profile in all dose cohorts. The reported adverse events were consistent with known GH-related side effects. CONCLUSIONS: Once-weekly MOD-4023 administration in GHD adults was found to be clinically effective while maintaining a favorable safety profile and may obviate the need for daily injections. Weekly GH injections may improve compliance and overall outcome. The promising results achieved in this Phase 2 study led to a pivotal Phase 3 trial, which is currently ongoing.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013350
003      
CZ-PrNML
005      
20220809115423.0
007      
ta
008      
170413s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1530/EJE-16-0748 $2 doi
035    __
$a (PubMed)27932411
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Strasburger, Christian J. $u Department of Medicine for EndocrinologyDiabetes and Nutritional Medicine, Charité Universitätsmedizin, Berlin, Germany. $7 xx0275498
245    10
$a MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults / $c CJ. Strasburger, P. Vanuga, J. Payer, M. Pfeifer, V. Popovic, L. Bajnok, M. Góth, V. Olšovská, L. Trejbalová, J. Vadasz, E. Fima, R. Koren, L. Amitzi, M. Bidlingmaier, O. Hershkovitz, G. Hart, BM. Biller,
520    9_
$a OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study's objective is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MOD-4023 administered once-weekly in GHD adults. DESIGN: 54 adults with GHD currently treated with daily GH were normalized and randomized into 4 weekly dosing cohorts of MOD-4023 at 18.5%, 37%, 55.5% or 123.4% of individual cumulative weekly molar hGH dose. The study included 2 stages: Stage A assessed the effectiveness and PK/PD profiles of the 4 dosing regimens of MOD-4023. Stage B was an extension period of once-weekly MOD-4023 administration (61.7% molar hGH content) to collect further safety data and confirm the results from Stage A. RESULTS: Dose-dependent response was observed for both PK and PD data of weekly MOD-4023 treatment. Insulin-like growth factor I (IGF-I) SDS levels were maintained within normal range. The 18.5% cohort was discontinued due to low efficacy. MOD-4023 was well tolerated and exhibited favorable safety profile in all dose cohorts. The reported adverse events were consistent with known GH-related side effects. CONCLUSIONS: Once-weekly MOD-4023 administration in GHD adults was found to be clinically effective while maintaining a favorable safety profile and may obviate the need for daily injections. Weekly GH injections may improve compliance and overall outcome. The promising results achieved in this Phase 2 study led to a pivotal Phase 3 trial, which is currently ongoing.
650    _2
$a dospělí $7 D000328
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hormonální substituční terapie $x metody $7 D020249
650    _2
$a lidský růstový hormon $x nedostatek $x terapeutické užití $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a hypopituitarismus $x farmakoterapie $7 D007018
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Vanuga, Peter $u Department of EndocrinologyNational Institute of Endocrinology and Diabetology, Lubochna, Slovakia.
700    1_
$a Payer, Juraj $u Department of Internal Medicine VUniversity Hospital Ruzinov, Bratislava, Slovakia.
700    1_
$a Pfeifer, Marija $u Department of EndocrinologyUniversity Medical Centre Ljubljana, Ljubljana, Slovenia.
700    1_
$a Popovic, Vera $u Neuroendocrine UnitClinical Centre of Serbia, Belgrade, Serbia.
700    1_
$a Bajnok, László $u 1st Department of MedicineUniversity of Pécs, Pécs, Hungary.
700    1_
$a Góth, Miklós $u 2nd Department of Internal MedicineMilitary Hospital - State Health Center, Budapest, Hungary.
700    1_
$a Olšovská, Věra $u II Internal Clinic in University Hospital St AnnaBrno, Czech Republic.
700    1_
$a Trejbalová, L'udmila $u I Department of Internal MedicineUniversity Hospital Bratislava, Bratislava, Slovakia.
700    1_
$a Vadasz, Janos $u 1st Department of Internal MedicineHetényi Géza Hospital and Out-Patient Clinic, Szolnok, Hungary.
700    1_
$a Fima, Eyal $u OPKO BiologicsKiryat Gat, Israel.
700    1_
$a Koren, Ronit $u OPKO BiologicsKiryat Gat, Israel.
700    1_
$a Amitzi, Leanne $u OPKO BiologicsKiryat Gat, Israel. $7 gn_A_00005642
700    1_
$a Bidlingmaier, Martin $u Medizinische Klinik - InnenstadtLudwig Maximilian University, Munich, Germany.
700    1_
$a Hershkovitz, Oren $u OPKO BiologicsKiryat Gat, Israel.
700    1_
$a Hart, Gili $u OPKO BiologicsKiryat Gat, Israel ghart@opko.com.
700    1_
$a Biller, Beverly M K $u Neuroendocrine UnitMassachusetts General Hospital, Boston, Massachusetts, USA.
773    0_
$w MED00009634 $t European journal of endocrinology $x 1479-683X $g Roč. 176, č. 3 (2017), s. 283-294
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27932411 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20220809115419 $b ABA008
999    __
$a ok $b bmc $g 1199815 $s 974128
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 176 $c 3 $d 283-294 $e 20161208 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace